论文部分内容阅读
目的探讨血清胸腺嘧啶核苷激酶1(TK1)、癌胚抗原(CEA)和糖类抗原153(CA153)水平与进展期乳腺癌化疗疗效及患者预后的关系。方法检测进展期乳腺癌患者血清TK1、CEA和CA153水平,化疗2个周期后对所有患者进行疗效评定,随访24个月。结果共入组85例进展期乳腺癌患者,随访结束疗效评定达完全缓解(CR)28例,部分缓解(PR)22例,疾病稳定(SD)18例,疾病进展(PD)17例。血清TK1、CEA和CA153指标联合预测患者发生PD的敏感度为60.0%,特异度为88.6%,其敏感度高于使用单项指标预测,特异度低于单独使用TK1,但高于单独使用CEA或CA153。结论 TK1、CEA和CA153是进展期乳腺癌有效的化疗疗效预测指标,联合检测可提高预测患者发生PD的灵敏度。
Objective To investigate the relationship between the serum levels of thymidine kinase 1 (TK1), carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153) and the prognosis of patients with advanced breast cancer. Methods The levels of serum TK1, CEA and CA153 in patients with advanced breast cancer were measured. All patients were evaluated after 2 cycles of chemotherapy and were followed up for 24 months. Results A total of 85 patients with advanced breast cancer were enrolled in this study. Twenty - eight patients with complete remission (CR), 22 with partial response (PR), 18 with stable disease (SD) and 17 with disease progression (PD) were evaluated at the end of follow - up. The combined detection of serum TK1, CEA and CA153 in patients with PD was 60.0% and 88.6%, respectively. The sensitivity was higher than that predicted by single index, and the specificity was lower than that of TK1 alone, but higher than that of CEA alone or CA153. Conclusions TK1, CEA and CA153 are effective predictors of chemotherapeutic response in advanced breast cancer. Combined detection may improve the sensitivity of predicting the occurrence of PD in patients with advanced breast cancer.